We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

88 hedge funds and large institutions have $314M invested in Catalyst Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 27 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more capital invested

Capital invested by funds: $94.3M → $314M (+$219M)

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

12.03% more ownership

Funds ownership: 47.83% → 59.85% (+12%)

2% more funds holding

Funds holding: 86 → 88 (+2)

7% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 27

43% less call options, than puts

Call options by funds: $683K | Put options by funds: $1.19M

Holders
88
Holders Change
+2
Holders Change %
+2.33%
% of All Funds
1.9%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.06%
New
15
Increased
25
Reduced
27
Closed
13
Calls
$683K
Puts
$1.19M
Net Calls
-$505K
Net Calls Change
-$424K

Top Buyers

1
CCM
Consonance Capital Management
New York
+$24.9M
2
OM
Opaleye Management
Massachusetts
+$5.36M
3
MP
Mangrove Partners
Connecticut
+$3.2M
4
KCM
Kennedy Capital Management
Missouri
+$2.94M
5
HRCM
Hawk Ridge Capital Management
California
+$1.93M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$2.76M
2
BC
Broadfin Capital
New York
-$1.21M
3
PAM
Panagora Asset Management
Massachusetts
-$920K
4
DMK
David M. Knott
-$302K
5
IG
ING Group
Netherlands
-$271K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
1
Consonance Capital Management
New York
$91.2M +$24.9M +8,473,338 +90%
BlackRock
2
BlackRock
New York
$35.6M +$52.5K +17,851 +0.3%
BC
3
Broadfin Capital
New York
$29.9M -$1.21M -411,300 -7%
Vanguard Group
4
Vanguard Group
Pennsylvania
$24.3M -$187K -63,777 -1%
MP
5
Mangrove Partners
Connecticut
$17.6M +$3.2M +1,088,711 +46%
BBA
6
Baker Bros. Advisors
New York
$14.8M – – –
Morgan Stanley
7
Morgan Stanley
New York
$11.8M -$2.76M -937,883 -29%
OM
8
Opaleye Management
Massachusetts
$9.31M +$5.36M +1,825,000 New
State Street
9
State Street
Massachusetts
$8.3M +$209K +71,118 +5%
AC
10
Armistice Capital
New York
$7.75M +$412K +140,000 +10%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$5.85M +$243K +82,654 +8%
Northern Trust
12
Northern Trust
Illinois
$5.75M -$3.81K -1,297 -0.1%
KCM
13
Kennedy Capital Management
Missouri
$5.1M +$2.94M +999,787 New
JP Morgan Chase
14
JP Morgan Chase
New York
$4.79M -$1.95K -662 -0.1%
HRCM
15
Hawk Ridge Capital Management
California
$3.34M +$1.93M +654,859 New
DMK
16
David M. Knott
$2.6M -$302K -102,600 -17%
EI
17
EAM Investors
California
$2.54M +$1.47M +498,844 New
GCM
18
Gables Capital Management
Florida
$2.45M -$2.94K -1,000 -0.2%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$2.34M +$369K +125,673 +38%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$2.08M -$18.5K -6,290 -2%
PAM
21
Panagora Asset Management
Massachusetts
$1.52M -$920K -312,811 -51%
EGI
22
EAM Global Investors
California
$1.41M +$812K +276,228 New
AA
23
ALPS Advisors
Colorado
$1.27M +$31.5K +10,715 +5%
RJFSA
24
Raymond James Financial Services Advisors
Florida
$1.21M – – –
TCM
25
Tanaka Capital Management
New York
$1.19M -$49.6K -16,889 -7%
1
2 3 4 5

CPRX Hedge Fund Activity: Q1 2019 in Review

88 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2019, worth a combined $314M — up 232% from $94.3M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CPRX positions and 13 closed out — a net gain of 2 holders — while 25 added to existing stakes and 27 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $24.9M. The largest seller was Morgan Stanley, cutting an estimated $2.76M.

  • 88 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2019, up from 86 in Q4 2018.
  • Funds reported $314M of Catalyst Pharmaceutical stock for Q1 2019, up 232% quarter-over-quarter.
  • 15 funds opened new Catalyst Pharmaceutical positions in Q1 2019 and 13 closed out, a net change of +2 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2019 was Consonance Capital Management, an estimated $24.9M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2019 was Morgan Stanley, an estimated $2.76M sold.

Based on aggregated 13F filings for Q1 2019.